Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

These Stocks Moved Moving the Most Today: Dayforce, Novo Nordisk, GoodRx, UnitedHealth, Sunrun, Duolingo, TeraWulf, and More ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with ...